>>Kort overzicht van de wetenschappelijke publicaties van Dr Luc LASSER

Luc LASSER

1: Degré D, Sersté T, Lasser L, Delwaide J, Starkel P, Laleman W, Langlet P, Reynaert H, Bourgeois S, Vanwolleghem T, Negrin Dastis S, Gustot T, Geerts A, Van Steenkiste C, de Galocsy C, Lepida A, Orlent H, Moreno C. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLoS One. 2017 Jan 26;12(1):e0170933. doi: 10.1371/journal.pone.0170933. eCollection 2017.
>PubMed

2: Vandenbulcke H, Moreno C, Colle I, Knebel JF, Francque S, Sersté T, George C, de Galocsy C, Laleman W, Delwaide J, Orlent H, Lasser L, Trépo E, Van Vlierberghe H, Michielsen P, van Gossum M, de Vos M, Marot A, Doerig C, Henrion J, Deltenre P. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol. 2016 Sep;65(3):543-51. doi: 10.1016/j.jhep.2016.04.031. Epub 2016 May 13.
>PubMed

3: Moreno C, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, Hittelet A, Piquet MA, Laleman W, Orlent H, Lasser L, Sersté T, Starkel P, De Koninck X, Negrin Dastis S, Delwaide J, Colle I, de Galocsy C, Francque S, Langlet P, Putzeys V, Reynaert H, Degré D, Trépo E. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. Gastroenterology. 2016 Apr;150(4):903-10.e8. doi: 10.1053/j.gastro.2015.12.038. Epub 2016 Jan 5.
>PubMed

4: Nkuize M, Mulkay JP, Moreno C, Lasser L, Michielsen P, de Galocsy C, Scheen R, Assene C, Delwaide J. Ethnic epidemiological profiles and antiviral therapy among patients infected with hepatitis C virus genotype 4: a multicenter study from Belgium. Acta Gastroenterol Belg. 2015 Dec;78(4):365-72.
>PubMed

5: Ghys C, Kong MF, Glibert G, Lasser L, Karmali R. A lady with NASH and choreoathetosis. Acta Clin Belg. 2015 Oct;70(5):375-6. doi: 10.1179/2295333715Y.0000000027. Epub 2015 Aug 17.
>PubMed

6: Mulkay JP, Bourgeois S, Lasser L, De Galocsy C, Tomasovic S, Horsmans Y, Van Vlierberghe H; Belgian PROPHESYS investigators. Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in belgium: a sub-analysis of the PROPHESYS study. Acta Gastroenterol Belg. 2014 Mar;77(1):30-40.
>PubMed

7: Nkuize M, Mulkay JP, Adler M, Lasser L, Michielsen P, de Galocsy C, Assene C, Delwaide J. Response of Black African patients with hepatitis C virus genotype 4 to treatment with peg-interferon and ribavirin. Acta Gastroenterol Belg. 2013 Sep;76(3):291-9.
>PubMed

8: Francque S, De Maeght S, Adler M, Deltenre P, de Galocsy C, Orlent H, Van Steenbergen W, Bastens B, Wain E, Langlet P, Lasser L, Verlinden W, Van Marck E, Henrion J; Steering Committee of the Belgian Association for the Study of the Liver. High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. Results of the Belgian NAFLD registry. Acta Gastroenterol Belg. 2011 Mar;74(1):9-16.
>PubMed

9: Moreno C, Langlet P, Hittelet A, Lasser L, Degré D, Evrard S, Colle I, Lemmers A, Devière J, Le Moine O. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010 Dec;53(6):1117-22. doi: 10.1016/j.jhep.2010.05.030. Epub 2010 Aug 1.
>PubMed

10: Gottignies P, Hossey D, Lasser L, Cherifi S, Devriendt J, De Bels D. Upper gastrointestinal bleeding related to emphysematous cholecystitis due to Clostridium perfringens. Int J Infect Dis. 2010 Mar;14(3):e257-8. doi: 10.1016/j.ijid.2009.04.004. Epub 2009 Aug 5.
>PubMed

11: Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL; EN-Vie (European Network for Vascular Disorders of the Liver). Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009 Aug 4;151(3):167-75.
>PubMed

12: Langlet P, D'Heygere F, Henrion J, Adler M, Delwaide J, Van Vlierberghe H, Mulkay JP, Lasser L, Brenard R, Horsmans Y, Michielsen P, Laureys A, Nevens F. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. Aliment Pharmacol Ther. 2009 Aug 15;30(4):352-63. doi: 10.1111/j.1365-2036.2009.04052.x. Epub 2009 May 26.
>PubMed

13: Lasser L, Langlet P. What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review. Acta Gastroenterol Belg. 2008 Jul-Sep;71(3):298-302. Review.
>PubMed

14: Mesquita M, Lasser L, Langlet P. Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis. Clin Nephrol. 2008 Jul;70(1):69-71.
>PubMed

15: Langlet P, Lasser L, Sidi B. [Hepatitis C in women planning a pregnancy: current opinions]. Rev Med Brux. 2005 Nov-Dec;26(6):487-91. Review. French.
>PubMed

!Gefiltreerde gegevens afkomstig van PubMed. U kunt de filter afschaffen om meer resultaten te krijgen (eventuele aanwezigheid van homoniemen).

>>Terug naar identiteitsfiche van Dr Luc LASSER.